Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

Diane V. Havlir, Matthew C. Strain, Mario Clerici, Caroline Ignacio, Daria Trabattoni, Pasquale Ferrante, Joseph K. Wong

Research output: Contribution to journalArticle

Abstract

To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 intensely monitored patients treated with indinavir and efavirenz sustaining HIV RNA at 5 years were studied. Abacavir was added to the regimen of eight patients at year 5. After the first 9 months of therapy, HIV RNA levels had reached a plateau ("residual viremia") that persisted for over 5 years. Levels of residual viremia differed among patients and ranged from 3.2 to 23 HIV RNA copies/ml. Baseline HIV DNA was the only significant pretreatment predictor of residual viremia in regression models including baseline HIV RNA, CD4 count, and patient age. In the four of five patients with detectable viremia who added abacavir to their regimen after 5 years, HIV RNA levels declined rapidly. The estimated half-life of infected cells was 6.7 days. Decrease in activated memory cells and a reduction in gamma interferon production to HIV Gag and p24 antigen in ELISpot assays were observed, consistent with a decrease in HIV replication. Thus, in patients treated with efavirenz plus indinavir, levels of residual viremia were established by 9 months, were predicted by baseline proviral DNA, and remained constant for 5 years. Even after years of highly suppressive therapy, HIV RNA levels declined rapidly after the addition of abacavir, suggesting that productive infection contributes to residual ongoing viremia and can be inhibited with therapy intensification.

Original languageEnglish
Pages (from-to)11212-11219
Number of pages8
JournalJournal of Virology
Volume77
Issue number20
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Viremia
viremia
Human immunodeficiency virus
Human immunodeficiency virus 1
HIV-1
HIV
therapeutics
Infection
infection
efavirenz
RNA
Indinavir
Therapeutics
gag Gene Products
DNA
CD4 Lymphocyte Count
Virus Replication
virus replication
interferon-gamma
Interferon-gamma

ASJC Scopus subject areas

  • Immunology

Cite this

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. / Havlir, Diane V.; Strain, Matthew C.; Clerici, Mario; Ignacio, Caroline; Trabattoni, Daria; Ferrante, Pasquale; Wong, Joseph K.

In: Journal of Virology, Vol. 77, No. 20, 10.2003, p. 11212-11219.

Research output: Contribution to journalArticle

Havlir, Diane V. ; Strain, Matthew C. ; Clerici, Mario ; Ignacio, Caroline ; Trabattoni, Daria ; Ferrante, Pasquale ; Wong, Joseph K. / Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. In: Journal of Virology. 2003 ; Vol. 77, No. 20. pp. 11212-11219.
@article{1b49a47861d6467aab41de2aa871a0d0,
title = "Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years",
abstract = "To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 intensely monitored patients treated with indinavir and efavirenz sustaining HIV RNA at 5 years were studied. Abacavir was added to the regimen of eight patients at year 5. After the first 9 months of therapy, HIV RNA levels had reached a plateau ({"}residual viremia{"}) that persisted for over 5 years. Levels of residual viremia differed among patients and ranged from 3.2 to 23 HIV RNA copies/ml. Baseline HIV DNA was the only significant pretreatment predictor of residual viremia in regression models including baseline HIV RNA, CD4 count, and patient age. In the four of five patients with detectable viremia who added abacavir to their regimen after 5 years, HIV RNA levels declined rapidly. The estimated half-life of infected cells was 6.7 days. Decrease in activated memory cells and a reduction in gamma interferon production to HIV Gag and p24 antigen in ELISpot assays were observed, consistent with a decrease in HIV replication. Thus, in patients treated with efavirenz plus indinavir, levels of residual viremia were established by 9 months, were predicted by baseline proviral DNA, and remained constant for 5 years. Even after years of highly suppressive therapy, HIV RNA levels declined rapidly after the addition of abacavir, suggesting that productive infection contributes to residual ongoing viremia and can be inhibited with therapy intensification.",
author = "Havlir, {Diane V.} and Strain, {Matthew C.} and Mario Clerici and Caroline Ignacio and Daria Trabattoni and Pasquale Ferrante and Wong, {Joseph K.}",
year = "2003",
month = "10",
doi = "10.1128/JVI.77.20.11212-11219.2003",
language = "English",
volume = "77",
pages = "11212--11219",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "20",

}

TY - JOUR

T1 - Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

AU - Havlir, Diane V.

AU - Strain, Matthew C.

AU - Clerici, Mario

AU - Ignacio, Caroline

AU - Trabattoni, Daria

AU - Ferrante, Pasquale

AU - Wong, Joseph K.

PY - 2003/10

Y1 - 2003/10

N2 - To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 intensely monitored patients treated with indinavir and efavirenz sustaining HIV RNA at 5 years were studied. Abacavir was added to the regimen of eight patients at year 5. After the first 9 months of therapy, HIV RNA levels had reached a plateau ("residual viremia") that persisted for over 5 years. Levels of residual viremia differed among patients and ranged from 3.2 to 23 HIV RNA copies/ml. Baseline HIV DNA was the only significant pretreatment predictor of residual viremia in regression models including baseline HIV RNA, CD4 count, and patient age. In the four of five patients with detectable viremia who added abacavir to their regimen after 5 years, HIV RNA levels declined rapidly. The estimated half-life of infected cells was 6.7 days. Decrease in activated memory cells and a reduction in gamma interferon production to HIV Gag and p24 antigen in ELISpot assays were observed, consistent with a decrease in HIV replication. Thus, in patients treated with efavirenz plus indinavir, levels of residual viremia were established by 9 months, were predicted by baseline proviral DNA, and remained constant for 5 years. Even after years of highly suppressive therapy, HIV RNA levels declined rapidly after the addition of abacavir, suggesting that productive infection contributes to residual ongoing viremia and can be inhibited with therapy intensification.

AB - To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 intensely monitored patients treated with indinavir and efavirenz sustaining HIV RNA at 5 years were studied. Abacavir was added to the regimen of eight patients at year 5. After the first 9 months of therapy, HIV RNA levels had reached a plateau ("residual viremia") that persisted for over 5 years. Levels of residual viremia differed among patients and ranged from 3.2 to 23 HIV RNA copies/ml. Baseline HIV DNA was the only significant pretreatment predictor of residual viremia in regression models including baseline HIV RNA, CD4 count, and patient age. In the four of five patients with detectable viremia who added abacavir to their regimen after 5 years, HIV RNA levels declined rapidly. The estimated half-life of infected cells was 6.7 days. Decrease in activated memory cells and a reduction in gamma interferon production to HIV Gag and p24 antigen in ELISpot assays were observed, consistent with a decrease in HIV replication. Thus, in patients treated with efavirenz plus indinavir, levels of residual viremia were established by 9 months, were predicted by baseline proviral DNA, and remained constant for 5 years. Even after years of highly suppressive therapy, HIV RNA levels declined rapidly after the addition of abacavir, suggesting that productive infection contributes to residual ongoing viremia and can be inhibited with therapy intensification.

UR - http://www.scopus.com/inward/record.url?scp=0141676556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141676556&partnerID=8YFLogxK

U2 - 10.1128/JVI.77.20.11212-11219.2003

DO - 10.1128/JVI.77.20.11212-11219.2003

M3 - Article

C2 - 14512569

AN - SCOPUS:0141676556

VL - 77

SP - 11212

EP - 11219

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 20

ER -